What type of injury is treated with methylprednisolone in liver transplant patients whose immune system is invading the graft?

Methylprednisolone is a corticosteroid that is used in liver transplant patients primarily to manage acute cellular rejection. This type of rejection occurs when the recipient's immune system recognizes the transplanted liver as foreign and mounts an immune response against it. By administering methylprednisolone, the inflammation and immune response can be reduced, thus helping to preserve the graft function and improve outcomes for the patient.

Acute vascular injury typically involves damage to the blood vessels supplying the graft, which is generally not primarily treated with corticosteroids. Chronic rejection, on the other hand, usually involves a more complex process that might require different therapeutic strategies including long-term immunosuppressants rather than just steroid treatment. Biliary complications refer to issues such as bile leaks or strictures, which again do not warrant treatment with methylprednisolone.

The use of methylprednisolone in the context of acute cellular rejection is well established, highlighting its role in dampening the immediate immune response and protecting the graft from damage.